Ann: Quarterly Activity Report & Appendix 4C, page-83

Why is everyone overlooking this quote?... overall quarterly was good in my opinion.

"Weformally commenced the process of engaging with global key opinion leaders around Zantrene, with valuable early feedback. We also reported third party market data which characterised what the potential opportunity, if successful, could look like for Zantrene under the cardio-protection and anticancer scenarios.We now move toward a planned strategic collaborative meeting with key opinion leaders in the last days of April, as we look to continue the team’s significant momentum. We are encouraged by the development of our new formulation, RC220 and our scientific results. With collaboration from our experienced scientific agency, Adnovate and our new team of clinical advisors, we are actively moving to further define our Target Product Profiles for Zantrene and to facilitate a clinical advisory board by June, enabling prioritisation of our resources and leading to enhancement of our Clinical Development Plans (CDP) by July/August. We will then be well positioned to execute on strategic commercialisation priorities for 2023 and beyond.”